Participant flow

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin · Source last updated 2026-09-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Pembrolizumab 200mg IV D1 + Romidepsin 14mg/m² IV D1, D8 q21d

   id

   FG000

   title

   Cohort 1

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         6

      type

      Adverse Event

   2. reasons

      1. group Id

         FG000

         num Subjects

         8

      type

      Death

   3. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Toxicity

   4. reasons

      1. group Id

         FG000

         num Subjects

         16

      type

      Progressive Disease

   5. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Withdrawal by Subject

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         38

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         4

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         34

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

This is a phase Ib/II study- and so there is no dose escalation- it was more safety run-in for Ib followed by phase II. There is only one arm since this is a single arm trial.

Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0

Preserved source evidence · Not medical advice